Abstracts tagged "risk factors"

Abstract Number: 1590 • ACR Convergence 2022
Pain and Treatment Switching Among Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Joshua Baker¹, J Morel Symons², Jud C Janak³, Oksana Pugach³, Elizabeth Kohl³, Miao Yu³, Dave Webb⁴, Alan A Martin⁴, Didier Saurigny⁵ and Marguerite Bracher⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ²GlaxoSmithKline, Collegeville, PA, ³CorEvitas, LLC, Waltham, MA, ⁴GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: For many patients with RA on targeted therapies, the chronic burden of pain leads to therapies being deemed suboptimally effective and may affect treatment…
Abstract Number: 2062 • ACR Convergence 2022
Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US
Sandra Sze-jung Wu¹, Allison Perry², Nicole Zimmerman³, Helen Varker⁴, Rich Bizier⁴, Liisa Palmer⁴, Christine Dube⁵ and Gary Bryant⁶, ¹AstraZeneca, Hockessin, DE, ²IBM Watson Health, New York, NY, ³IBM Watson Health, Chagrin Falls, OH, ⁴Merative, Cambridge, MA, ⁵AstraZeneca, Torrington, CT, ⁶AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex disease with multisystem inflammation resulting in variable clinical manifestations. As a result, predicting the occurrence of an…
Abstract Number: 0680 • ACR Convergence 2022
Association of Environmental Risk Factors with Antiphospholipid Antibodies and Thrombosis in 1199 International Patients Referred for Suspected Antiphospholipid Syndrome
Medha Barbhaiya¹, Deanna Jannat-Khah, DrPH, MSPH¹, Jonah Levine¹, Karen Costenbader² and Doruk Erkan¹, ¹Hospital for Special Surgery, New York, NY, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Whether environmental risk factors induce antiphospholipid antibody (aPL) positivity and increase the risk of arterial thrombosis (AT) and venous thromboembolism (VTE) in aPL-positive patients…
Abstract Number: 1207 • ACR Convergence 2022
Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid
Huan Meng¹, Steven H Lam², Ho So¹ and Lai-shan Tam³, ¹The Faculty of Medicine, CUHK, Hong Kong, Hong Kong, ²The Chinese university of Hong Kong, Hong Kong, Hong Kong, ³The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: Inflammatory arthritis (IA) including rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to systematic inflammation. To elucidate whether inflammatory…
Abstract Number: 1591 • ACR Convergence 2022
Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population
Sandra Sze-jung Wu¹, Gelareh Atefi², Meghan Moynihan³, Kristin Evans³, Liisa Palmer³, Michael Pollack², Christine Dube⁴ and Cassandra Calabrese⁵, ¹AstraZeneca, Hockessin, DE, ²AstraZeneca, Wilmington, DE, ³Merative, Cambridge, MA, ⁴AstraZeneca, Torrington, CT, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH
Background/Purpose: To assess the prevalence of severe COVID-19 (COVID) overall and following vaccination among patients with systemic lupus erythematosus (SLE) and the general population, and…
Abstract Number: 2067 • ACR Convergence 2022
Predictors of Organ Damage Accrual by Domains
Rangi Kandane-Rathnayake¹, Ning Li¹, Vera Golder¹, Worawit Louthrenoo², Yi-Hsin Chen³, Jiacai Cho⁴, Aisha Lateef⁵, Laniyati Hamijoyo⁶, Luo Shue Fen⁷, Yeong-Jian Wu⁷, Sandra Navarra⁸, Leonid Zamora⁹, Zhanguo Li¹⁰, An Yuan¹¹, Sargunan Sockalingam¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹³, Yanjie Hao¹⁴, Zhouli Zhang¹⁵, Madelynn Chan¹⁶, Jun Kikuchi¹⁷, Tsutomu Takeuchi¹⁸, Shereen Oon¹⁹, Sang-Cheol Bae²⁰, Fiona Goldblatt²¹, Sean O'Neill²², Kathy Gibson²², Kristine Ng²³, Hui Nee Annie Law²⁴, Duminda Basnayake²⁵, Nicole Tugnet²⁶, Sunil Kumar²⁷, Cherica Tee²⁸, Michael Tee²⁸, Yoshiya Tanaka²⁹, Chak Sing³⁰, Mandana Nikpour³¹, Alberta Hoi³² and Eric Morand³³, ¹Monash University, Clayton, Australia, ²Chiang Mai University, Chiang Mai, Thailand, ³Taichung Veterans General Hospital, Taichung, Taiwan, ⁴National University Health System (NUHS), Singapore, Singapore, ⁵National University Hospital, Singapore, Singapore, ⁶Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁷Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁸University of Santo Tomas, Manila, Philippines, ⁹University of Santo Tomas Hospital, Manila, Philippines, ¹⁰People's Hospital, Peking University Health Science Center, Beijing, China, ¹¹Peking University Health Science Center, Beijing, China, ¹²University of Malaya, Kuala Lumpur, Malaysia, ¹³Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ¹⁴The University of Melbourne, Melbourne, Australia, ¹⁵Peking University First Hospital, Beijing, China, ¹⁶Tan Tock Seng Hospital, Singapore, Singapore, ¹⁷Keio University, Tokyo, Japan, ¹⁸Keio University and Saitama Medical University, Tokyo, Japan, ¹⁹St Vincent's Hospital, Fitzroy, Australia, ²⁰Hanyang University Medical Center, Seoul, Republic of Korea, ²¹Flinders Medical Centre, Adelaide, Australia, ²²Liverpool Hospital, Sydney, Australia, ²³North Shore Hospital, Auckland, New Zealand, ²⁴Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²⁵Teaching Hospital Kandy, Kandy, Sri Lanka, ²⁶Greenlane Clinical Centre, Auckland, New Zealand, ²⁷Middlemore Hospital, Auckland, New Zealand, ²⁸University of the Philippines, Quezon City, Philippines, ²⁹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ³⁰The University of Hong Kong, Pok Fu Lam, Hong Kong, ³¹The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, ³²Monash Health, Melbourne, Australia, ³³Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia
Background/Purpose: Prevention of organ damage is one of the main treatment goals in systemic lupus erythematosus (SLE).The SLICC/ACR Damage Index (SDI) is used to quantify…
Abstract Number: 0682 • ACR Convergence 2022
Analysis of Recurrent Thrombotic Events in a Large Single-center Primary Antiphospholipid Syndrome Cohort: Results from APS-Rio Cohort After over Than 600 Patients-year of Follow-up
Gustavo Balbi¹, Guilherme de Jesús² and Flavio Victor Signorelli², ¹Universidade de São Paulo, São Paulo, Brazil, ²Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil
Background/Purpose: To estimate the incidence rate of new thrombotic events in a large single-center prospective cohort of primary antiphospholipid syndrome (PAPS) patients after approximately 5.5…
Abstract Number: 1222 • ACR Convergence 2022
Association of Fibromyalgia, PTSD and Combat Deployments in Active Duty Military
James Dizmang¹ and Jeanne Tofferi², ¹US Air Force, Vacaville, CA, ²US Army, Ft Sam Houston, TX
Background/Purpose: Many combat veterans experience unexplained symptoms with long-term disability including chronic pain, irritability, headaches, fatigue, behavioral health conditions, and memory difficulty. These invisible wounds…
Abstract Number: 1657 • ACR Convergence 2022
Extreme Phenotype Approach Identifies Rare Variants in Systemic Sclerosis and Dermatomyositis Patients with Severe Calcinosis
Srijana Davuluri¹, Urvashi Kaundal², Christian Lood³, Puneet Kapoor¹, Yumeko Kawano⁴, Stefania Dell'Orso⁵, Zuoming Deng⁶, Zsuzsanna McMahan⁷, Ami Shah⁷, Laura Hummers⁸, Daniel Kastner⁹, Fredrick Wigley¹⁰, David Fiorentino¹¹, Pravitt Gourh¹² and Lorinda Chung¹¹, ¹Stanford University School of Medicine, Palo Alto, CA, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³Division of Rheumatology, University of Washington, Seattle, WA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵NIH, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷Johns Hopkins Rheumatology, Baltimore, MD, ⁸Johns Hopkins Univerisity, Baltimore, MD, ⁹National Human Genome Research Institute, Bethesda, MD, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Stanford University, Stanford, CA, ¹²National Institutes of Health, Bethesda, MD
Background/Purpose: Calcinosis, deposition of insoluble calcium salts in skin and subcutaneous tissues, affects up to 40% of systemic sclerosis (SSc) patients, and up to 20%…
Abstract Number: 2073 • ACR Convergence 2022
The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies
Laurence S Magder¹, Andrea Fava², Daniel W. Goldman³ and Michelle Petri³, ¹University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: An important clinical question is whether treatments (e.g, corticosteroids, immunosuppressants) or SLE disease activity are associated with an increased risk of COVID-19 infection among…
Abstract Number: 0518 • ACR Convergence 2021
Predicted Expression of Genes Involved in the Thiopurine Metabolic Pathway Is Associated with Azathioprine Discontinuation Due to Bone Marrow Toxicity
Laura Daniel¹, Alyson Dickson², Jacy Zanussi², Tyne Miller-Fleming², Peter Straub², Wei-Qi Wei², Dale Plummer², William Dupont³, Ge Liu², Prathima Anandi², Tyler Reese², Kelly Birdwell², Vivian Kawai⁴, Adriana Hung², Nancy J. Cox², Qiping Feng², C. Michael Stein² and Cecilia Chung², ¹Vanderbilt University Medical Center, Pegram, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN, ⁴Vanderbilt Universty Medical Center, Nashville, TN
Background/Purpose: Azathioprine is a thiopurine used to treat inflammatory conditions; however, it is often discontinued due to dose-dependent bone marrow toxicity. The Pharmacogenomics Knowledgebase (PharmGKB)…
Abstract Number: 1052 • ACR Convergence 2021
Female Reproductive Factors and Risk of Joint Replacement Arthroplasty of the Knee and Hip Due to Osteoarthritis in Postmenopausal Women: A Nationwide Cohort Study of 1.36 Million Women
Yeonghee Eun¹, Jung Eun Yoo², Kyungdo Han³, Dahye Kim³, Jaejoon Lee¹, Dong-Yun Lee¹, Dae-Hee Lee¹, Dong Wook Shin¹ and Hyungjin Kim¹, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Republic of Korea, ³Soongsil University, Seoul, Republic of Korea
Background/Purpose: Previous studies of the relationships between female reproductive factors and osteoarthritis (OA) have shown conflicting results. In this study, we aimed to explore the…
Abstract Number: 1800 • ACR Convergence 2021
Altered Metabolic Profiles in the Transition from Psoriasis to Psoriatic Arthritis: A Longitudinal Analysis
Ananta Paine¹, Paul Brookes², Dongmei Li³, Somyaroop Bhattacharya⁴, Maria de la Luz Garcia-Hernandez¹ and Christopher Ritchlin¹, ¹Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ²Department of Pharmacology & Physiology, University of Rochester Medical Center, Rochester, NY, ³Department of Clinical and Translational Research, University of Rochester Medical Center, Rochester, NY, ⁴Division of Neonatology, Department of Pediatrics, University of Rochester, Rochester, NY
Background/Purpose: The transition to psoriatic arthritis (PsA) occurs in 20-30% of psoriasis (Ps) patients, but the mechanisms underlying the emergence of musculoskeletal disease are not…
Abstract Number: 0017 • ACR Convergence 2021
Lessons Learnt from Associations Between Anti-modified Protein Antibodies and Risk Factors: Human Leukocyte Antigen – Shared Epitope Alleles Solely Associate with Anti-citrullinated Protein Antibodies
Tineke J van wesemael, Annemarie L. Dorjee, Tom WJ Huizinga, Annette H.M van der Helm-van Mil, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the presence of auto-antibodies to post translationally modified proteins (anti-modified protein antibodies (AMPA)): anti-citrullinated protein antibodies (ACPA), anti-carbamylated…
Abstract Number: 0576 • ACR Convergence 2021
Associations of the MUC5B Promoter Variant with Timing of Articular Diagnosis and Interstitial Lung Disease in Rheumatoid Arthritis
Gregory McDermott¹, Ritu Gill², Staci Gagne³, Suzanne Byrne³, Weixing Huang³, Jing Cui⁴, Lauren Prisco⁵, Alessandra Zaccardelli³, Lily Martin³, Nancy Shadick⁶, Paul Dellaripa³, Tracy Doyle⁷ and Jeffrey Sparks³, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Pound Ridge, MA, ⁶Brigham & Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: The common promoter variant of MUC5B (G >T, rs35705950) is associated with increased mucin 5B production in lung parenchyma and is an established genetic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].